Division of Pharmacogenomics

Medicine & Life Sciences

1. 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid 12%
2. 7-(3-(3-hydroxy-4-(4'-iodophenoxy)-1-butenyl)-7-oxabicyclo(2.2.1)heptan-2-yl)-5-heptenoic acid 7%
3. Adenylyl Cyclases 8%
4. Adrenergic Agents 16%
5. Adrenergic Receptors 40%
6. African Americans 9%
7. Apoptosis 23%
8. Autophagy 17%
9. Binding Sites 7%
10. Blood Platelets 19%
11. Calcineurin 6%
12. Calcium 18%
13. Calsequestrin 6%
14. Cardiac Myocytes 100%
15. Cardiomegaly 47%
16. Cardiomyopathies 54%
17. Cardiovascular Diseases 6%
18. Cell Death 14%
19. Cyclic GMP-Dependent Protein Kinases 10%
20. Dideoxynucleotides 8%
21. Dilatation 6%
22. Dilated Cardiomyopathy 20%
23. DNA 11%
24. DNA Methylation 18%
25. DNA Sequence Analysis 8%
26. Down-Regulation 7%
27. Drosophila 11%
28. Endoplasmic Reticulum 8%
29. Epigenomics 7%
30. Fibroblast Growth Factor 2 8%
31. Fibroblasts 7%
32. Fibrosis 8%
33. G-Protein-Coupled Receptor Kinase 2 36%
34. Gene Expression 18%
35. Genes 30%
36. Genome 12%
37. Genotype 7%
38. Growth 14%
39. GTP Phosphohydrolases 7%
40. Heart 72%
41. Heart Diseases 23%
42. Heart Failure 73%
43. High-Throughput Nucleotide Sequencing 8%
44. Homeostasis 8%
45. human PPP1R2C protein 7%
46. Hypertrophy 50%
47. In Vitro Techniques 6%
48. Ischemia 9%
49. Ligands 7%
50. Mass Spectrometry 6%
51. Membranes 7%
52. Messenger RNA 15%
53. Methylation 19%
54. MicroRNAs 25%
55. Mitochondria 51%
56. Mitochondrial Diseases 7%
57. Mitochondrial Dynamics 73%
58. mitochondrial permeability transition pore 6%
59. Mitochondrial Proteins 12%
60. Mitochondrial Transmembrane Permeability-Driven Necrosis 6%
61. Mitophagy 41%
62. Mortality 7%
63. Muscle Cells 19%
64. Mutation 17%
65. Myocardial Infarction 14%
66. Myocardium 12%
67. Myosin Heavy Chains 8%
68. Necrosis 9%
69. Nucleotides 6%
70. Organelle Biogenesis 8%
71. Organelles 12%
72. Pharmacogenetics 7%
73. Pharmacology 6%
74. Phenotype 17%
75. phospholamban 28%
76. Phosphorylation 16%
77. Phosphotransferases 11%
78. Pressure 10%
79. Prostaglandin H2 11%
80. Prostaglandin H2 Receptors Thromboxane A2 35%
81. Protein Isoforms 9%
82. Protein Kinase C 35%
83. Proteins 17%
84. Quality Control 15%
85. Reactive Oxygen Species 8%
86. Reperfusion Injury 6%
87. RNA 6%
88. RNA Sequence Analysis 6%
89. Sarcoplasmic Reticulum 32%
90. Single Nucleotide Polymorphism 14%
91. Smooth Muscle Myocytes 9%
92. Therapeutics 8%
93. Thromboxane A2 23%
94. Thromboxane Receptors 12%
95. Thromboxanes 10%
96. Transgenic Mice 27%
97. Type 2A Charcot-Marie-Tooth disease 23%
98. Type C Phospholipases 7%
99. Vascular Smooth Muscle 20%
100. Ventricular Remodeling 13%